tiprankstipranks
Blurbs

H.C. Wainwright Sticks to Its Buy Rating for Kiora Pharmaceuticals (KPRX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Kiora Pharmaceuticals (KPRXResearch Report) today and set a price target of $10.00. The company’s shares closed yesterday at $3.39.

Chen covers the Healthcare sector, focusing on stocks such as Vaccitech Plc, Veru, and Prophase Labs. According to TipRanks, Chen has an average return of -12.8% and a 29.21% success rate on recommended stocks.

Kiora Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

See Insiders’ Hot Stocks on TipRanks >>

KPRX market cap is currently $6.09M and has a P/E ratio of -0.08.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles